I
Immunetrics
A biosimulation company, developes predictive computer models based on biological responses towards diseases and intervention
About Immunetrics
Immunetrics specializes in creating predictive biological models that simulate drug targets and clinical trials. These models are designed to inform decisions at every stage of drug development, from preclinical targeting to FDA requests. The company serves pharmaceutical and biotechnology firms, providing them with tools to optimize trial designs, evaluate combination drug synergies, and identify target patient populations. Immunetrics operates in the healthcare and life sciences market, leveraging advanced mathematics, biology, and software engineering to build its models. The business model includes licensing their models for use in projects or within their Thales model development platform, which incorporates AI and machine learning to enhance model-building processes. Revenue is generated through licensing fees and consulting services, including clinical trial simulations and optimization.
Source: Dealroom company dataAt a glance
- Founded
- 2001
- Headquarters
- Pittsburgh, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A3 investors entered at this stage
Pittsburgh Life Sciences Greenhouse
Philips
LaunchCyte
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunetrics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunetrics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.